PROACT 2.0: a new open-source tool to improve patient-doctor communication in clinical trials
Name:
PROACT 2.0....pdf
Size:
572.7Kb
Format:
PDF
Description:
Found with Open Access Button
Authors
Agnelli, L.Villa, A.
Butt, F.
Duca, M.
Guidi, A.
Carapezza, M.
Addante, M.
Lenoci, G.
O'Regan, P.
Russo, L.
Cresta, S.
Castano, A.
Ebrahem, E.
Alfieri, S.
Patil, A.
Carter, Louise
Dive, C.
De Braud, F. G.
Damian, S.
Affiliation
The Christie NHS Foundation Trust, Manchester, UK.Issue Date
2024
Metadata
Show full item recordAbstract
The use of Digital Healthcare Products is leading to significant improvements in clinical practice. Herein, we discuss the development of PROACT 2.0 (Patient Reported Opinions About Clinical Tolerability v2.0), a novel open-source mobile and web application developed at Fondazione IRCCS Istituto Nazionale Tumori in Milan. It was developed in collaboration with The Christie, Manchester, in the context of work package 2 of the UpSMART Accelerator project, involving a consortium of referral cancer centers from the UK, Spain and Italy. PROACT 2.0 enhances communication between patients and healthcare providers in cancer clinical trials, allowing patients to report adverse events and side effects, and healthcare teams to collect valuable patient-reported outcome measures for treatment management. PROACT 2.0 supports text, audio, and video messaging, offering a secure, non-urgent communication channel that integrates with, or replaces, traditional methods. Its user-friendly and multilingual interface provides a new route for patient engagement and streamlines the handling of logistical information. Positive feedback from initial testing warrants future enhancements for broader applicability in cancer research and treatment.Citation
Agnelli L, Villa A, Butt F, Duca M, Guidi A, Carapezza M, et al. PROACT 2.0: A new open-source tool to improve patient-doctor communication in clinical trials. Tumori. 2024 Apr 27:3008916241248007. PubMed PMID: 38676437. Epub 2024/04/27. eng.Journal
TumoriDOI
10.1177/03008916241248007PubMed ID
38676437Additional Links
https://dx.doi.org/10.1177/03008916241248007Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1177/03008916241248007
Scopus Count
Collections
Related articles
- Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT.
- Authors: Hughes A, Landers D, Arkenau HT, Shah S, Stephens R, Mahal A, Simmons M, Lemech C, Royle J
- Issue date: 2016 Jun
- [Voluntary mediation in healthcare disputes: the experience of the "Fondazione IRCCS Istituto Nazionale dei Tumori" in Milan (Italy)].
- Authors: Tereanu C, Bettega S, Regalia E, Mazza R, Greco M, Lozza L, Saita L, Borreani C, Quattrocolo A
- Issue date: 2014 Jan-Feb
- The organization of clinical trials for oncology at IRCCS Istituto Nazionale Tumori "Fondazione G. Pascale" Napoli and the impact of the OECI accreditation process.
- Authors: De Feo G, D'Ambrosio F, Palmieri G, Perrone F, Ciliberto G
- Issue date: 2015
- Development of an eHealth Tool for Capturing and Analyzing the Immune-related Adverse Events (irAEs) in Cancer Treatment.
- Authors: Moradian S, Ghasemi S, Boutorabi B, Sharifian Z, Dastjerdi F, Buick C, Lee CT, Mayo SJ, Morita PP, Howell D
- Issue date: 2023
- [Adolescents with cancer: the "Youth Project" at the Istituto Nazionale Tumori in Milan].
- Authors: Ferrari A, Veneroni L, Clerici CA, Spreafico F, Terenziani M, Massimino M, Luksch R, Casanova M, Meazza C, Polastri D, Gandola L
- Issue date: 2013 Jan